Foghorn Therapeutics Inc. filings document a clinical-stage biotechnology issuer with common stock listed on the Nasdaq Global Market under FHTX. The company’s current-event filings cover financial results, Regulation FD investor presentations, oncology pipeline disclosures for FHD-909 and selective CBP, EP300 and ARID1B degrader programs, and collaboration-related revenue.
Proxy and 8-K filings also address annual-meeting voting matters, board and executive governance, officer appointments, compensatory arrangements, material agreements, capital-structure disclosures and security-registration details tied to the company’s common stock and financing activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many Foghorn Therapeutics (FHTX) SEC filings are available on StockTitan?
StockTitan tracks 32 SEC filings for Foghorn Therapeutics (FHTX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Foghorn Therapeutics (FHTX)?
The most recent SEC filing for Foghorn Therapeutics (FHTX) was filed on August 5, 2025.